High levels of serum IL-10 indicate disease progression,extramedullary involvement,and poor prognosis in multiple myeloma  

作　　者：Xiaoyan YUE Linlin HUANG Yang YANG Yi ZHAO Donghua HE Xiaoyan HAN Gaofeng ZHENG Yi LI Enfan ZHANG Zhen CAI Xin HUANG Jingsong HE 

机构地区：[1]Bone Marrow Transplantation Center,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China [2]Institute of Hematology,Zhejiang University,Hangzhou 310058,China [3]Zhejiang Laboratory for Systems&Precision Medicine,Zhejiang University Medical Center,Hangzhou 311121,China [4]Institute of Hematology,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2022年第11期968-974,共7页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：the National Natural Science Foundation of China(Nos.81800201 and 81872322);the Zhejiang Key Research and Development Project(No.2020C03014);the Key Project of Zhejiang Provincial Natural Science Foundation of China(No.LZ22H160009)。

摘　　要：Multiple myeloma(MM)is a common malignant hematological tumor in adults,which is characterized by clonal malignant proliferation of plasma cells in the bone marrow and secretion of a large number of abnormal monoclonal immunoglobulins(M protein),leading to bone destruction,hypercalcemia,anemia,and renal insufficiency(Alexandrakis et al.,2015;Yang et al.,2018).Since a large number of new drugs,represented by proteasome inhibitors and immunomodulators,have been successfullyused to treat MM.

关 键 词：al. INVOLVEMENT MYELOMA 

分 类 号：R733.3[医药卫生—肿瘤]